PPT-Brentuximab
Vedotin Should be the Second Line Regimen of Choice for Recurrent Hodgkin Lymphoma Prior to Stem Cell Transplant Catherine Diefenbach MD Assistant Professor of Medicine
Download Presentation
"Brentuximab" is the property of its rightful owner. Permission is granted to download and print materials on this website for personal, non-commercial use only, provided you retain all copyright notices. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
Transcript not available.